Physician profile
Nathan Moore Morrow
NPI 1184146771
$6,493.65
in general payments reported to CMS, 2019-2025
32 companies · $739 in 2025
The $739 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $365 · 2021: $1,219 · 2022: $848 · 2023: $1,072 · 2024: $1,002 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,812.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $984.96 | 2020-2025 | Idose, Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Lensar, INC. | $752.40 | 2019-2021 | |
| Allergan, INC. | $715.31 | 2019-2021 | |
| Alcon Vision LLC | $466.95 | 2019-2025 | Wavelight Refractive Suite, Rocklatan, Tryptyr |
| Dompe US, INC. | $465.33 | 2021-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $324.33 | 2022-2025 | Lotemax Sm, Alrex, Zylet |
| Abbvie INC. | $316.79 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $310.82 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $286.34 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $284.84 | 2019-2021 | |
| Coopervision INC. | $237.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $183.70 | 2019-2023 | |
| Rxsight INC | $142.33 | 2020-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Johnson & Johnson Vision Care, INC. | $127.36 | 2023 | Acuvue |
| Astellas Pharma US INC | $121.18 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $119.13 | 2019 | |
| Sun Pharmaceutical Industries INC. | $89.29 | 2020 | |
| Thea Pharma INC. | $82.99 | 2024-2025 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $80.40 | 2023-2025 | Acthar |
| Biotissue Holdings INC. | $66.11 | 2021-2024 | |
| Lombart Brothers, INC. | $55.00 | 2019 | |
| Oyster Point Pharma, INC. | $47.39 | 2023-2024 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $36.67 | 2025 | Vevye |
| Sight Sciences, INC. | $34.45 | 2021 | |
| Ani Pharmaceuticals, INC. | $33.22 | 2024 | Purified Cortrophin Gel |
| Shire North American Group INC | $32.40 | 2019 | |
| Quidel Corporation | $21.28 | 2019 | |
| Alimera Sciences, INC. | $20.88 | 2024 | Yutiq, Iluvien |
| New World Medical,INC. | $16.33 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.26 | 2022 | |
| Ocular Therapeutix, INC. | $12.49 | 2021 | |
| Kala Pharmaceuticals, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.